A total artificial heart is an implantable mechanical device that completely replaces both ventricles of a failing heart, taking over the job of pumping blood to the lungs and the rest of the body. Unlike ventricular assist devices, which work alongside a damaged heart, a total artificial heart requires removing the patient’s native ventricles entirely. The technology has been used in over 1,700 patients, almost always as a temporary bridge to keep someone alive while waiting for a donor heart transplant.1Nature Reviews Cardiology. The ongoing quest for the first total artificial heart as destination therapy Despite more than six decades of development, making these devices work as a permanent replacement remains an unsolved engineering and biological challenge.
How the Field Got Here
The idea of mechanically replacing the heart dates back further than most people realize. In 1937, Soviet scientist Vladimir Demikhov built a two-pump device driven by an external motor through a shaft that passed through the skin and implanted it in a dog, which survived for about five and a half hours. Twenty years later, Tetsuzo Akutsu and Willem Kolff at the Cleveland Clinic implanted a total artificial heart in an animal that lived for ninety minutes. The first human implant came in 1969, performed by Denton Cooley in Houston as an emergency bridge to keep a patient alive until a donor heart became available.2PubMed Central. Evolution of Artificial Hearts: An Overview and History
The case that lodged the concept in public consciousness came in 1982, when surgeons at the University of Utah implanted the Jarvik-7 permanent artificial heart in a retired dentist named Barney Clark. He survived 112 days, tethered to a large pneumatic console. The device worked, but the quality of life it offered and the infections it produced made clear how far the technology had to go. The modern successor to that device, renamed the CardioWest and later the SynCardia total artificial heart, received FDA approval in 2004 specifically for bridging patients to transplant. A different device called the AbioCor, which was fully implantable with no external tubes, gained limited FDA approval in 2006 but was never widely adopted.3PubMed Central. Evolution of Artificial Hearts: An Overview and History
Who Needs One
A total artificial heart is reserved for people with end-stage biventricular heart failure, meaning both sides of the heart are failing. This is a critical distinction. The far more common left ventricular assist device (LVAD) helps patients whose left ventricle is failing but whose right ventricle still functions adequately. When both ventricles are beyond recovery and mechanical support of just one side will not be enough, a total artificial heart becomes the option. Certain structural problems, like failed previous heart transplants, massive heart tumors, or unrepairable congenital defects, can also make someone a candidate.
Body size matters in a very concrete way. The standard SynCardia device has 70 cc ventricles and requires sufficient chest space to fit, generally a body surface area above 1.7 square meters. That threshold excludes many women and nearly all children. An early comparison of mechanical support strategies found that unstable patients with biventricular failure should receive a total artificial heart if their body surface area exceeds that cutoff, or an alternative biventricular assist configuration if they are smaller.4PubMed. Comparison of the CardioWest total artificial heart, the novacor left ventricular assist system and the thoratec ventricular assist system in bridge to transplantation This size limitation has been one of the device’s most persistent equity problems.
How the Device Works
The SynCardia total artificial heart, which is by far the most implanted device of its kind, uses a pneumatic design. Two polyurethane ventricles sit in the chest where the native ventricles used to be. Compressed air is pumped in through drive lines that exit through the skin and connect to an external console or a portable driver the patient can carry. When air pressure fills a chamber behind each diaphragm, blood is pushed out through mechanical valves, mimicking the squeeze of a natural heartbeat. The device generates a pulse, and you can hear it clicking if you stand close enough to the patient.
The external driver is one of the defining burdens of life on a total artificial heart. The original hospital consoles were the size of a small refrigerator. Portable drivers small enough to fit in a shoulder bag now allow patients to leave the hospital, but the drive lines exiting the abdomen remain a permanent vulnerability, creating an open pathway for bacteria to reach deep tissue.
Life on the Device
Patients supported by a total artificial heart can walk, eat, and interact with family, but their daily reality revolves around the device. The external driver must be powered at all times, and the drive lines require meticulous wound care. Because the SynCardia device pumps at a roughly fixed rate, cardiac output does not ramp up the way a healthy heart does during exertion. Yet the body can still adapt. In one documented case, a patient on a CardioWest total artificial heart completed 29 months of cardiac rehabilitation and achieved a 24% increase in peak oxygen consumption, despite having a fixed peak cardiac output. The improvement came from peripheral adaptation: muscles getting better at extracting oxygen from the blood they received.5PubMed. Peripheral adaptation mechanisms in physical training and cardiac rehabilitation: the case of a patient supported by a CardioWest total artificial heart
That finding illustrates something counterintuitive about living with a mechanical heart. Even though the pump itself cannot be trained, the rest of the cardiovascular system, skeletal muscles, and metabolic pathways can still improve. Rehabilitation programs for these patients focus on exactly that.
Complications That Define the Experience
Three categories of complications dominate life on a total artificial heart: infection, stroke, and bleeding. Understanding the tradeoffs between them helps explain why managing these patients is so demanding.
Infection is the most relentless problem, particularly along the drive lines that exit the body. A study of the four longest-surviving Jarvik-7 recipients found that infection spreading from the drive lines into the mediastinum, the deep space around the device, was the major limiting factor in long-term use. The organisms involved were common skin bacteria, particularly staphylococci and Pseudomonas species, that traveled inward along the tubes.6JAMA. Infectious Complications in Four Long-term Recipients of the Jarvik-7 Artificial Heart This problem has never been fully solved in any pneumatic device with percutaneous drive lines. It is managed, not eliminated.
Stroke is the other major neurological threat. Blood contacting artificial surfaces tends to form clots, and those clots can break free and travel to the brain. Most strokes in total artificial heart patients are caused by embolism of thrombotic fragments originating on prosthetic surfaces.7PubMed Central. Stroke and the total artificial heart: neurologic considerations To prevent this, patients take a combination of blood thinners and antiplatelet drugs for as long as the device is in place. One center reported that after the first two postoperative days, using a protocol involving heparin, aspirin, dipyridamole, and pentoxifylline, the embolic stroke rate dropped to 0.08 per patient year across nearly 100 recipients, with no spontaneous hemorrhagic strokes.8ASAIO Journal. Results with an Anticoagulation Protocol in 99 SynCardia Total Artificial Heart Recipients
The price of aggressive anticoagulation is bleeding. In that same cohort, about one in five patients experienced post-implant bleeding, mostly in the first week after surgery. Around 4% developed gastrointestinal bleeding.9ASAIO Journal. Results with an Anticoagulation Protocol in 99 SynCardia Total Artificial Heart Recipients Other programs have used bivalirudin and warfarin alongside antiplatelet agents, with careful monitoring through clotting studies and even warfarin genomics testing to fine-tune dosing.10PubMed Central. Antithrombotic therapy for the CardioWest temporary total artificial heart The balancing act between preventing clots and causing bleeds is a daily clinical puzzle that never fully resolves.
Outcomes After Transplant
The total artificial heart is overwhelmingly used as a bridge to transplant, so the most meaningful outcome is what happens after patients receive a donor heart. The news here is mixed. A study using 15 years of U.S. transplant registry data found that patients bridged with a total artificial heart had lower ten-year survival, around 53%, compared to about 62% for patients bridged with an LVAD and roughly 63% for those transplanted without any bridge device.11PubMed Central. Heart transplantation after total artificial heart bridging-Outcomes over 15 years That gap is real, but it narrows considerably when you look at patients who survive the first year post-transplant. At that point, conditional ten-year survival was nearly identical across all groups, hovering around 67 to 69%.12PubMed Central. Heart transplantation after total artificial heart bridging-Outcomes over 15 years
The early mortality difference appears to be driven by the condition these patients are in at the time of transplant. Total artificial heart recipients are generally sicker to begin with and arrive at transplant with higher rates of kidney injury. They had roughly ten times the rate of dialysis dependence compared to LVAD-bridged patients, about 25% versus under 3%.13PubMed Central. Heart transplantation after total artificial heart bridging-Outcomes over 15 years They were also more likely to die from multiorgan failure in the first post-transplant year. A separate analysis confirmed a similar pattern, with five-year post-transplant mortality around 29% for total artificial heart patients compared to about 15% for those bridged with an LVAD, with higher rates of post-transplant kidney complications in the total artificial heart group.14PubMed. Heart Transplant Outcomes After Total Artificial Heart The device itself is not necessarily harming transplant outcomes so much as the patients who need it tend to be in worse shape.
The Sizing Problem and Smaller Patients
The standard 70 cc SynCardia device fits comfortably in a large adult male chest but physically cannot fit in many women or adolescents. This has been a recognized problem for decades. SynCardia developed a smaller 50 cc version specifically to serve patients with a body surface area as low as 1.2 square meters, potentially opening total artificial heart support to a population that previously had limited biventricular support options.15PubMed. The 50/50 cc Total Artificial Heart Trial: Extending the Benefits of the Total Artificial Heart to Underserved Populations This matters for equity: the vast majority of total artificial heart implants historically have gone to adult males, not because biventricular failure is uncommon in other groups, but because the hardware could not accommodate them.
In pediatric patients, the story is similar. The 50 cc device expanded the potential for use in older children and adolescents.16PubMed Central. The total artificial heart in pediatrics: outcomes in an evolving field For younger and smaller children, researchers have been developing a pediatric continuous-flow total artificial heart. Early animal experiments in lambs showed good anatomical fit and stable hemodynamics, with the device’s self-regulating performance maintaining balanced pressures between the left and right sides.17The Journal of Heart and Lung Transplantation. Early in vivo experience with the pediatric continuous-flow total artificial heart These are still early-stage efforts, but they represent a recognition that one size has never fit all.
The Pulse Question
One of the more unsettling ideas in modern cardiac engineering is whether a person actually needs a pulse. Continuous-flow pumps, which spin blood through a turbine at a constant rate rather than squeezing it in rhythmic pulses, have become standard in left ventricular assist devices. Extending that concept to a total artificial heart raises the stakes because the entire circulation becomes pulseless.
In a landmark animal study, a calf supported by a continuous-flow total artificial heart lived for seven weeks with no detectable pulse. The researchers found no hemolysis, no clotting, and normal physiological responses including the ability to exercise on a treadmill. The calf gained weight and appeared to function normally.18PubMed Central. Continuous-flow total artificial heart supports long-term survival of a calf End-organ function and the ability to regulate blood vessel tone were preserved despite the complete absence of a pulse. That experiment was a proof of concept that pulseless circulation is survivable, at least for weeks.
Still, the long-term effects of pulselessness remain debated, particularly on smaller blood vessels, the gut lining, and the kidneys. Some engineers have been working on a middle ground: using speed modulation in continuous-flow pumps to recreate something resembling a normal blood pressure waveform. In bench testing, an optimized speed profile could generate a physiologic-looking pulse at a cost of only about 16% more power consumption compared to steady flow.19PubMed Central. Speed Modulation of the Continuous-Flow Total Artificial Heart to Simulate a Physiologic Arterial Pressure Waveform This approach could offer the durability advantages of continuous-flow designs while hedging against unknown risks of fully pulseless circulation.
Why There Is No Permanent Artificial Heart Yet
After six decades of research, no total artificial heart has been approved as a permanent replacement for the human heart. The reasons are interconnected: device durability, blood compatibility, infection risk from drive lines, device bulk, and quality of life. Any one of these might be solvable in isolation, but solving all of them simultaneously in a single device has proven extraordinarily difficult.20Nature Reviews Cardiology. The ongoing quest for the first total artificial heart as destination therapy
Blood compatibility alone is a formidable challenge. Every artificial surface that blood touches triggers clotting cascades and damages red blood cells. Computational modeling of one positive-displacement heart design identified leakage flow through the bileaflet mechanical valves as the primary site of red blood cell destruction.21PubMed. Assessment of haemolysis models for a positive-displacement total artificial heart The problem is not just the main pumping chambers but every junction, valve, and seam where blood flow becomes turbulent or stagnant.
One of the more innovative attempts to address this is the Aeson device, originally developed by the French company Carmat. It uses a bioprosthetic membrane, partly made from bovine pericardial tissue, as the blood-contacting surface instead of bare plastic. Hemodynamic simulations predicted very low levels of hemolysis and platelet activation with this design, with shear stresses across the vast majority of blood volume staying well below harmful thresholds.22Heliyon. Preclinical evaluation of the hybrid membrane of the Carmat bioprosthetic total artificial heart The device also features autoregulation, meaning it can increase its output when filling pressures rise, somewhat mimicking how a healthy heart responds to increased demand. The first U.S. implant of the Aeson device, part of an early feasibility study, successfully bridged a patient to transplant after five months of support.23Elsevier / ScienceDirect. The First Autoregulated Total Artificial Heart Implant in the United States
Soft Robotics and the Next Generation
The most radical departure from conventional artificial hearts comes from soft robotics. Instead of rigid housings, mechanical valves, and hard plastic surfaces, these devices use flexible silicone structures that deform under pneumatic pressure, squeezing blood through chambers in a motion closer to how a real heart contracts. An injection-molded silicone total artificial heart demonstrated a total cardiac output exceeding 16 liters per minute against physiological pressures on a bench model and ran continuously for 110,000 cycles.24PubMed. Increased Longevity and Pumping Performance of an Injection Molded Soft Total Artificial Heart That is impressive flow capacity, but 110,000 cycles translates to only about a day and a half at a normal heart rate, so durability remains the core limitation of soft designs.
A more recent approach combines soft robotics with biological materials. A hybrid total artificial heart uses a pneumatically driven soft actuator as a septum between two ventricles, coated with supramolecular polymers designed to promote anti-thrombotic properties and even support growth of the patient’s own cells on the device surface. In bench testing it pumped 5.7 liters per minute and mimicked the heart’s ability to adapt its output. Proof-of-concept animal studies in rats and an acute goat model showed promise.25PubMed Central. A soft robotic total artificial hybrid heart The idea of lining an artificial heart with the patient’s own cells is appealing because it could eliminate the need for lifelong anticoagulation, but translating bench demonstrations into a device that lasts years inside a human chest is a challenge that has humbled every previous generation of engineers.
Costs and Access
Total artificial hearts are among the most expensive therapies in medicine. Estimates of the cost per patient in the initial year have ranged from $100,000 to $300,000, covering the surgical procedure, the device and console, and ongoing medical surveillance. Projections that tried to model what would happen if the technology scaled up to serve tens of thousands of patients estimated total program costs in the billions within five years.26PubMed. The artificial heart. Costs, risks, and benefits–an update Those projections are old, and actual per-patient costs today are likely higher given the complexity of modern devices and the intensity of postoperative care. The economic reality has been part of why total artificial hearts remain a niche therapy rather than a widely deployed solution, even for the patients who could benefit.
When the Device Becomes the Problem
Because a total artificial heart completely replaces the patient’s ventricles, turning it off means death. This creates unique ethical territory. If a patient on a total artificial heart develops a devastating stroke, untreatable cancer, or another condition that makes continued life support futile or contrary to their wishes, the question of withdrawing the device becomes urgent and deeply uncomfortable.
Legal and ethical frameworks generally support the right of patients or their surrogates to refuse or request the withdrawal of life-sustaining treatment, including mechanical hearts. That right is grounded in bodily integrity, codified in nearly every U.S. state’s legislation, and upheld by the judicial system including the Supreme Court.27PubMed Central. Ethical Analysis of Withdrawing Total Artificial Heart Support In principle, withdrawing a total artificial heart is no different from discontinuing a ventilator or dialysis. In practice, the irreversibility and directness of the act, where stopping the machine stops the heartbeat immediately, makes it feel different to families and care teams even when the ethical reasoning is clear.
There is also a broader allocation question. Because the total artificial heart is almost exclusively a bridge to transplant, implanting one effectively creates a new competitor for a scarce donor organ. Every patient placed on a total artificial heart enters the transplant waiting list with high urgency, potentially displacing someone who was waiting without mechanical support. This dynamic means that the device creates its own incentive within the donor pool, a tension that has prompted calls for policies to address the orderly deployment of pretransplant total artificial hearts.28PubMed. The total artificial heart. An ethics perspective on current clinical research and deployment The scarcity of donor hearts is the fundamental constraint that makes the total artificial heart necessary, and simultaneously the reason its use raises fairness concerns.